We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » What Device Manufacturers Can Learn From FDA’s Inspection Data

What Device Manufacturers Can Learn From FDA’s Inspection Data

FDA_Logo_Blue_2016.gif
July 14, 2017

Medical device quality managers that don’t want to wind up a statistic in a future FDA report on quality deviations should dig deeply into the agency’s recently released report on inspections, Form 483s and warning letters, says Michael Gaba, a partner in the law firm Polsinelli.

The agency released CY2016 Annual FDA Medical Device Quality System Data Inspections, FDA Form 483 Observations, and Warning Letter Citations, says Gaba, to give companies a peek into data collected by the FDA during inspections so they can see what’s happening across the regulated industry.

The report “lets you see trends, which can show you potential problems that you should be focusing on because the odds are that you too will find yourself in the same bucket of deviations,” says Gaba, who will present an FDAnews webinar on lessons from the FDA report August 9.

For example, he says, it’s helpful for foreign companies to know foreign inspections increased while domestic inspections decreased. It’s also helpful to know that foreign companies got slapped with an Official Action Indicated (OAI) after an inspection 12 percent of the time, when domestic companies got OAIs 7 percent of the time.

“U.S. companies seem to be doing a better job getting it right,” says Gaba, which he added may be a function of their having been in the market and subjected to FDA regulations for longer.

Companies in China, Germany and the United Kingdom should take heed, as they are the companies most often getting OAIs.

In 2016, FDA issued 854 Form 483s, and 3,027 Form 483 observations were cited for 21 CFR 820 (Quality System regulation) deficiencies. Two thirds of those observations fell into the categories of Corrective and Preventive Action (CAPA) and Production and Process Controls (P&PC). CAPA and P&PC continue to be the most frequently observed and cited quality subsystems.

View today's stories

Devices Quality

    Upcoming Events

    • 07Dec

      Proactive Supplier Management Using Quality Agreements

    • 13Dec

      FDA Inspection Overhaul: How Things Have Changed in 2023

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • FDA Laboratory-Developed Tests Proposal Comments Pour In by Thousands

    • Healthcare Titans Expand Their Portfolios in Acquisition Deals

    • Ups and Downs of Gene Therapy Weighed by FDA’s Marks

    • Device Manufacturers Pressed by Europe’s MDCG to Get Certified ASAP

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing